CN Patent

CN113637003B — 一种制备2-氨基-6-（哌啶-4-酰基）吡啶衍生物的方法

Assigned to Lunan Pharmaceutical Group Corp · Expires 2024-03-19 · 2y expired

What this patent protects

本发明属于药物合成技术领域，具体涉及一种制备2‑氨基‑6‑(哌啶‑4‑酰基)吡啶衍生物的方法；本发明采用铵盐和碱为原料，代替了现有技术中用氨气进行反应，避免了高温高压操作的危险。本发明的反应条件温和，操作过程简便，生产成本低，产品具有较高的纯度、收率。

USPTO Abstract

本发明属于药物合成技术领域，具体涉及一种制备2‑氨基‑6‑(哌啶‑4‑酰基)吡啶衍生物的方法；本发明采用铵盐和碱为原料，代替了现有技术中用氨气进行反应，避免了高温高压操作的危险。本发明的反应条件温和，操作过程简便，生产成本低，产品具有较高的纯度、收率。

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: CN113637003B
Jurisdiction: CN
Classification: —
Expires: 2024-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Lunan Pharmaceutical Group Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.